DGAP-News: Cytos Biotechnology Ltd announces hosting of Investor&Analyst Day in NYC
(firmenpresse) - EQS Group-News: Cytos Biotechnology AG / Key word(s): Research Update
Cytos Biotechnology Ltd announces hosting of Investor&Analyst Day in
NYC
17.10.2013 / 18:00
---------------------------------------------------------------------
Cytos Biotechnology Ltd to host Investor and Analyst R&D Day in New York
City
Schlieren (Zurich), Switzerland, October 18, 2013 - Cytos Biotechnology Ltd
(SIX:CYTN) will host an Investor and Analyst R&D Day for institutional
investors and research analysts on
Christian Itin, Chairman and CEO as well as senior executives of Cytos will
present on Cytos' lead program CYT003, which is in clinical development for
the treatment of allergic asthma.
Expert medical and scientific leaders in the field of asthma clinical
research will be featured speakers at the meeting:
- Thomas B. Casale, MD, Professor of Medicine, University of South
Florida School of Medicine, Tampa, Florida
- Kai-Michael Beeh, MD, Medical Director of insaf Respiratory Research
Institute, Wiesbaden, Germany
A live webcast of the Investor and Analyst R&D Day can be accessed by
visiting the investor relations section of Cytos' website at:
http://www.videonewswire.com/event.asp?id=96505
Participant Dial-in numbers for conference call:
Participant Dial In (Toll Free): + 1-877-870-4263For further information, please contact:
Participant International Dial In: + 1-412-317-0790
Cytos Biotechnology Ltd
Harry Welten
Chief Financial Officer
Tel: +41 44 733 46 46
harry.welten(at)cytos.com
US Investor enquiries
Susan A. Noonan
Tel: +1 (212) 966 3650
susan(at)sanoonan.com
About Cytos Biotechnology Ltd
Cytos is a public biopharmaceutical company focused on the development of
targeted immuno-therapies. The Company's lead product candidate CYT003 is a
novel, first-in-class, immune modulator in Phase 2 clinical development as
a potential new treatment for asthma.
CYT003 has a novel mechanism of action that inhibits the immune response
that causes asthma, and may therefore be beneficial for the control of
asthma. In a successfully completed Phase 2a study, CYT003 was shown to
maintain asthma control and lung function in patients with persistent
allergic asthma, despite withdrawal of standard therapy with inhaled
corticosteroids. CYT003 has been shown to have a good safety and
tolerability profile in more than 450 individuals receiving the active
agent so far.
Cytos was founded in 1995 as a spinoff from the Swiss Federal Institute of
Technology (ETH) in Zurich. It is located in Schlieren (Zurich),
Switzerland. The Company is listed according to the Main Standard on the
SIX Swiss Exchange Ltd under the symbol CYTN.
www.cytos.com
Forward Looking Statements
This media release contains certain forward-looking statements that involve
risks and uncertainties that could cause actual results to be materially
different from historical results or from any future results expressed or
implied by such forward-looking statements. You are urged to consider
statements that include the words 'will' or 'expect' or the negative of
those words or other similar words to be uncertain and forward-looking.
Factors that may cause actual results to differ materially from any future
results expressed or implied by any forward-looking statements include
scientific, business, economic and financial factors, including that CYT003
may not demonstrate safety or efficacy in clinical trials, that there may
be delays in development or that CYT003 may not receive marketing approval,
and that the Company relies on outside financing to meet capital
requirements, which may not be available under acceptable terms or at all.
Against the background of these uncertainties, readers should not rely on
forward-looking statements. The Company assumes no responsibility for
updating forward-looking statements or adapting them to future events or
developments.
End of Corporate News
+++++
Additional features:
Document: http://n.equitystory.com/c/fncls.ssp?u=POQPHLDBRR
Document title: Cytos Analyst Day NYC_131018
---------------------------------------------------------------------
17.10.2013 This Corporate News was distributed by EQS Schweiz AG.
www.eqs.com - news archive: http://switzerland.eqs.com/de/News
The issuer is responsible for the contents of the release.
---------------------------------------------------------------------
Language: English
Company: Cytos Biotechnology AG
Wagistr. 25
8952 Schlieren
Switzerland
Phone: +41 44 733 4747
Fax: +41 44 733 4740
E-mail: info(at)cytos.com
Internet: www.cytos.com
ISIN: CH0011025217, CH0029060735
Valor: -
Listed: Freiverkehr in Berlin, München, Stuttgart; Frankfurt in
Open Market ; SIX
End of News EQS Group News-Service
---------------------------------------------------------------------
235119 17.10.2013
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 17.10.2013 - 18:00 Uhr
Sprache: Deutsch
News-ID 306882
Anzahl Zeichen: 6832
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 321 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Cytos Biotechnology Ltd announces hosting of Investor&Analyst Day in NYC"
steht unter der journalistisch-redaktionellen Verantwortung von
Cytos Biotechnology AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
